Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

19.13
+0.35001.86%
Post-market: 19.130.00000.00%19:30 EDT
Volume:1.41M
Turnover:26.47M
Market Cap:1.13B
PE:1.66
High:19.88
Open:18.64
Low:18.08
Close:18.78
52wk High:34.63
52wk Low:6.50
Shares:59.16M
Float Shares:37.23M
Volume Ratio:2.11
T/O Rate:3.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):11.53
EPS(LYR):-70.5015
ROE:-125.43%
ROA:-21.37%
PB:-5.65
PE(LYR):-0.27

Loading ...

Vor Bio Grants Inducement Stock Options for 59,250 Shares, RSUs for 12,550 Shares to New Hires

Reuters
·
Oct 06

Vor Bio Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Oct 06

Long Lasting Symptom Relief Data Could Be A Game Changer For Vor Biopharma Stock

Simply Wall St.
·
Oct 05

U.S. Stocks on the MOVE-Snowflake, Cboe, Oracle

Reuters
·
Sep 29

US Stocks on the MOVE-Veracyte, Staar Surgical, Corning

Reuters
·
Sep 29

Vor Biopharma Rises After Positive Autoimmune Drug Data

Reuters
·
Sep 29

Vor Bio Says Telitacicept Phase 3 Analysis Shows 42% Minimal Symptom Expression in gMG Through 48 Weeks

Reuters
·
Sep 29

Vor Biopharma Inc: More than 94% of Participants Achieved a ≥5-Point Mg-Adl Improvement at Week 48

THOMSON REUTERS
·
Sep 29

Vor Biopharma Inc: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

Vor Biopharma Inc: Telitacicept was Generally Well Tolerated Through 48 Weeks with no New Safety Signals Observed

THOMSON REUTERS
·
Sep 29

Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Sep 28

Citi Keeps Their Buy Rating on Vor Biopharma (VOR)

TIPRANKS
·
Sep 10

Vor Bio completes enrollment in UPSTREAM MG trial

TIPRANKS
·
Sep 08

Vor Bio Completes Enrollment in Phase 3 Upstream MG Trial for Telitacicept in Generalized Myasthenia Gravis

Reuters
·
Sep 08

Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

THOMSON REUTERS
·
Sep 08

Vor Biopharma - Upstream Mg 24-Week Primary Endpoint Results Expected in First Half of 2027

THOMSON REUTERS
·
Sep 08

Vor Bio files automatic mixed securities shelf

TIPRANKS
·
Sep 05

Vor Biopharma Inc. - Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Sep 05

Vor Bio Grants 83,600 Stock Options, 17,900 RSUs to New Hires Under Inducement Plan

Reuters
·
Sep 05

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Aug 31